Sichuan Haisco Pharmaceutical
As of the edition of 20 October 2026, Sichuan Haisco Pharmaceutical runs 4 drugs, 1 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Went quiet | 1 |
| Total | 4 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Cipepofol | Ends 2031 (exclusivity) | 0 |
A route B row is one company at one target.
Where its trials are
- Hormones: 3 trials led
- Nutrition and metabolism: 3 trials led